Multi-criteria decision analysis of value evaluation of rare disease medical insurance drugs in China
This study initially constructed a value evaluation system for the inclusion of rare disease drugs in medical insurance, based on MCDA and multi-stakeholder perspectives. However, the system relied heavily on expert opinions and lacks empirical analysis. Given the complexity of real-world applications, further validation is necessary to assess the system's applicability and feasibility.
Authors
- Yafei Duan (ORCID: https://orcid.org/0000-0002-5557-8147)
- Yan Yan Wu (ORCID: https://orcid.org/0000-0003-1553-1392)
- Ruixia Gu (ORCID: https://orcid.org/0000-0002-6186-4318)
- Zhinan Cao
- Jiatong Wang (ORCID: https://orcid.org/0000-0002-0158-8032)
- Kexin Chen (ORCID: https://orcid.org/0000-0003-4248-7681)
- Bin Jiang (ORCID: https://orcid.org/0000-0001-5777-9842)
Institutions
- Chinese University of Hong Kong (HK)
- Peking University (CN)
- Nankai University (CN)
- Hong Kong Jockey Club (HK)
Publication Details
- Journal
- BMC Public Health
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1186/s12889-025-23831-9
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Nankai University